Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Article first published online: 29 SEP 2009
© 2009 Japanese Cancer Association
Volume 101, Issue 2, pages 440–447, February 2010
How to Cite
Bijnsdorp, I. V., Kruyt, F. A. E., Fukushima, M., Smid, K., Gokoel, S. and Peters, G. J. (2010), Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Science, 101: 440–447. doi: 10.1111/j.1349-7006.2009.01375.x
- Issue published online: 29 JAN 2010
- Article first published online: 29 SEP 2009
- (Received June 8, 2009/Revised September 8, 2009/Accepted September 22, 2009/Online publication November 4, 2009)
- 1Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–75., , et al.
- 2Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214–32., , .
- 3Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007; 98: 779–89., , , , .
- 4A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004; 13: 545–9., , , , .
- 5Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 2007; 43: 175–83., , , .
- 6Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007; 96: 231–40., , , , , .
- 7Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin Colorectal Cancer 2004; 4: 51–62., .
- 8Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51: 147–52., , et al.
- 9The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454–60., , , , , .
- 10Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Lett 2005; 225: 61–74., , , .
- 11Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006; 94: 1136–43., , et al.
- 12EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007; 62: 53–61., , , .
- 13The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int J Biol Markers 2007; 22: S47–52., , , .
- 14Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007; 13: 3413–22., , , .
- 15Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008; 73: 1290–300., , et al.
- 16Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer Chemother Pharmacol 2009; 64: 67–72., , , , , , , , , .
- 17Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24: 1892–7., , , , , , , , , , .
- 18Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Ann Oncol 2007; 18: 1185–9., , , , , , , , , , , .
- 19Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 2008; 99: 2302–8., , , , .
- 20Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 1999; 94: 3121–8., , et al.
- 21Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer 2009; 100: 1120–7., , , , , .
- 22Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines. Oncol Res 1999; 11: 383–91., , .
- 23ZD1893 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9: 4735–42., , et al.
- 24Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159: 439–52., , , , , .
- 25Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008; 68: 9141–6., , , , .
- 26Targeted drugs in chronic myeloid leukemia. Curr Med Chem 2008; 15: 3036–51., .
- 27Molecularly targeted therapy in breast cancer: the new generation. Recent Pat Anticancer Drug Discov 2008; 3: 100–4..
- 28Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008; 7: 599–606., , et al.
- 29Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108: 464–72., , , , , , , , .
- 30Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328–35., , , , , , , .
- 31Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006; 5: 1154–65., , et al.
- 32Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803–1810., , et al.
- 33Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 2005; 5 (Suppl 2): S98–S100..
- 34Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111: 2170–80., , et al.
- 35Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 2008; 76: 1417–25., , et al.
- 36Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs 2006; 17: 921–8., , , , .
- 37Sequence dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16 (Suppl 4): iv 61–68., , et al.
- 38The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550–65., .
- 39Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273: 1568–73., , , , .
- 40Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 2007; 74: 1555–67., , , .